Dopaminergic and Serotonergic Degeneration and Cortical [
Parkinson's disease
cortical degeneration
nigrostriatal degeneration
striatum
thalamus
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
28
04
2021
received:
12
02
2021
accepted:
02
05
2021
pubmed:
23
5
2021
medline:
25
2
2023
entrez:
22
5
2021
Statut:
ppublish
Résumé
Degeneration of the nigrostriatal dopaminergic (DA) and the raphe-thalamic serotonergic (SE) systems is among the earliest changes observed in Parkinson's disease (PD). The consequences of those changes on brain metabolism, especially regarding their impact on the cortex, are poorly understood. Using multi-tracer molecular imaging, we assessed in a cohort of drug-naive PD patients the association between cortical metabolism and DA and SE system deafferentation of either striatum or thalamus, and we explored whether this association was mediated by either striatum or thalamus metabolism. We recruited 96 drug-naive PD patients (aged 71.9 ± 7.5 years) who underwent [ We found that [ These data suggest that the impact of deep gray matter monoaminergic deafferentation on cortical function is mediated by striatal and thalamic metabolism in drug-naive PD. © 2021 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Degeneration of the nigrostriatal dopaminergic (DA) and the raphe-thalamic serotonergic (SE) systems is among the earliest changes observed in Parkinson's disease (PD). The consequences of those changes on brain metabolism, especially regarding their impact on the cortex, are poorly understood.
OBJECTIVES
Using multi-tracer molecular imaging, we assessed in a cohort of drug-naive PD patients the association between cortical metabolism and DA and SE system deafferentation of either striatum or thalamus, and we explored whether this association was mediated by either striatum or thalamus metabolism.
METHODS
We recruited 96 drug-naive PD patients (aged 71.9 ± 7.5 years) who underwent [
RESULTS
We found that [
CONCLUSIONS
These data suggest that the impact of deep gray matter monoaminergic deafferentation on cortical function is mediated by striatal and thalamic metabolism in drug-naive PD. © 2021 International Parkinson and Movement Disorder Society.
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2293-2302Informations de copyright
© 2021 International Parkinson and Movement Disorder Society.
Références
Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8(12):1150-1157.
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:1-21. https://doi.org/10.1038/nrdp.2017.13.
Schindlbeck KA, Lucas-Jiménez O, Tang CC, et al. Metabolic network abnormalities in drug-naïve Parkinson's disease. Mov Disord 2020;35(4):587-594.
Apostolova I, Lange C, Frings L, Klutmann S, Meyer PT, Buchert R. Nigrostriatal degeneration in the cognitive part of the striatum in Parkinson disease is associated with Frontomedial Hypometabolism. Clin Nucl Med 2020;45(2):95-99.
Berti V, Polito C, Ramat S, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37(3):537-544.
Roselli F, Pisciotta NM, Pennelli M, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord 2010;25(12):1853-1859. https://doi.org/10.1002/mds.23179.
Koch W, Unterrainer M, Xiong G, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging 2014;41(10):1938-1946. https://doi.org/10.1007/s00259-014-2785-8.
Arnaldi D, Famà F, De Carli F, et al. The role of the serotonergic system in REM sleep behavior disorder. Sleep 2015;38(9):1505-1509.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56(1):33-39.
Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18 F] FDG, version 2. Eur J Nucl Med Mol Imaging 2009;36(12):2103.
Orso B, Arnaldi D, Famà F, et al. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's disease. Cortex 2020;130:401-412.
Gutierrez D, Montandon M-L, Assal F, et al. Anatomically guided voxel-based partial volume effect correction in brain PET: impact of MRI segmentation. Comput Med Imaging Graph 2012;36(8):610-619.
Chételat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008;131(1):60-71.
Della Rosa PA, Cerami C, Gallivanone F, et al. A standardized [18 F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014;12(4):575-593.
Mattioli P, Pardini M, Famà F, et al. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. Eur J Nucl Med Mol Imaging 2021;48:1-12. https://doi.org/10.1007/s00259-021-05205-6.
Nobili F, Naseri M, De Carli F, et al. Automatic semi-quantification of [123 I] FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 2013;40(4):565-573.
Pilotto A, di Cola FS, Premi E, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2019;46(8):1642-1651. https://doi.org/10.1007/s00259-019-04324-5.
Cohen J. The effect size. Stat power Anal Behav Sci. 1988;2:77-83.
Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease. Neurobiol Dis 2019;124:29-35.
Eggers C, Schwartz F, Pedrosa DJ, Kracht L, Timmermann L. Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum. PLoS One 2014;9(5):e96629.
Alberquilla S, Gonzalez-Granillo A, Martín ED, Moratalla R. Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner. Neurobiol Dis 2020;134:104666.
Caravaggio F, Nakajima S, Plitman E, et al. The effect of striatal dopamine depletion on striatal and cortical glutamate: a mini-review. Prog Neuro-Psychopharmacology Biol Psychiatry 2016;65:49-53.
Eaton SA, Salt TE. Modulatory effects of serotonin on excitatory amino acid responses and sensory synaptic transmission in the ventrobasal thalamus. Neuroscience 1989;33(2):285-292.
McKie S, Del-Ben C, Elliott R, et al. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005;180(4):680-686. https://doi.org/10.1007/s00213-005-2270-y.
Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res 2015;277:136-145.
Duval C, Daneault J-F, Hutchison WD, Sadikot AF. A brain network model explaining tremor in Parkinson's disease. Neurobiol Dis 2016;85:49-59.
Wu L, Liu F, Ge J, et al. Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in 18F-FDG PET imaging. Hum Brain Mapp 2018;39(12):4652-4662.
Firbank MJ, Yarnall AJ, Lawson RA, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry 2017;88(4):310-316.
Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52(6):848-855.
Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15(2):88-93.
Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study. Brain 2018;141(3):811-821.
Jellinger KA. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochim Biophys Acta (BBA)-Molecular Basis Dis. 2009;1792(7):730-740.
Meles SK, Renken RJ, Pagani M, et al. Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging 2020;47(2):437-450.
Braak H, Del Tredici K, Rüb U, De Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
Bora E, Walterfang M, Velakoulis D. Theory of mind in Parkinson's disease: a meta-analysis. Behav Brain Res 2015;292:515-520. https://doi.org/10.1016/j.bbr.2015.07.012.
Planetta PJ, Schulze ET, Geary EK, et al. Thalamic projection fiber integrity in de novo Parkinson disease. Am J Neuroradiol 2013;34(1):74-79.
Cropper EC, Eisenman JS, Azmitia EC. An immunocytochemical study of the serotonergic innervation of the thalamus of the rat. J Comp Neurol 1984;224(1):38-50.
Varela C. Thalamic neuromodulation and its implications for executive networks. Front Neural Circuits 2014;8:69.
Saalmann YB. Intralaminar and medial thalamic influence on cortical synchrony, information transmission and cognition. Front Syst Neurosci 2014;8:83.
Wu P, Wang J, Peng S, et al. Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord 2013;19(6):622-627.
Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain 2015;138(10):2964-2973.
Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ. [18F] FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F] FDOPA and [11C] DASB PET study in Parkinson's disease. Neuroimage 2012;59(2):1080-1084.
Fu JF, Klyuzhin I, Liu S, et al. Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. NeuroImage Clin 2018;19:652-660.
Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage 2011;56(3):1463-1468.
Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage 2009;45(2):260-266.